DE69535876D1 - Nadh-oxidase als zielmolekül in diagnose und therapie - Google Patents

Nadh-oxidase als zielmolekül in diagnose und therapie

Info

Publication number
DE69535876D1
DE69535876D1 DE69535876T DE69535876T DE69535876D1 DE 69535876 D1 DE69535876 D1 DE 69535876D1 DE 69535876 T DE69535876 T DE 69535876T DE 69535876 T DE69535876 T DE 69535876T DE 69535876 D1 DE69535876 D1 DE 69535876D1
Authority
DE
Germany
Prior art keywords
nadh oxidase
cells
therapy
inhibitors
normal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69535876T
Other languages
English (en)
Inventor
D James Morre
Stephen R Byrn
Frederick L Crane
Dorothy M Morre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/222,799 external-priority patent/US5605810A/en
Priority claimed from US08/248,084 external-priority patent/US5569673A/en
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69535876D1 publication Critical patent/DE69535876D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69535876T 1994-04-05 1995-04-04 Nadh-oxidase als zielmolekül in diagnose und therapie Expired - Fee Related DE69535876D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/222,799 US5605810A (en) 1994-04-05 1994-04-05 NADH oxidase assay for neoplasia determination
US08/248,084 US5569673A (en) 1994-05-24 1994-05-24 Capsacinoid compounds as proliferation inhibitors
PCT/US1995/004237 WO1995026743A1 (en) 1994-04-05 1995-04-04 Nadh oxidase as a target in diagnosis and therapy

Publications (1)

Publication Number Publication Date
DE69535876D1 true DE69535876D1 (de) 2008-12-11

Family

ID=26917153

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535876T Expired - Fee Related DE69535876D1 (de) 1994-04-05 1995-04-04 Nadh-oxidase als zielmolekül in diagnose und therapie

Country Status (7)

Country Link
EP (1) EP0752872B1 (de)
JP (1) JPH10503921A (de)
AT (1) ATE412769T1 (de)
AU (1) AU701529B2 (de)
CA (1) CA2187200A1 (de)
DE (1) DE69535876D1 (de)
WO (1) WO1995026743A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6875575B1 (en) 1998-11-25 2005-04-05 Osi Pharmaceuticals, Inc. Diagnostic methods for neoplasia
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US7053188B2 (en) 2002-02-22 2006-05-30 Purdue Research Foundation Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase
US7491413B2 (en) 2005-09-30 2009-02-17 Purdue Research Foundation Compositions and methods for treating and preventing virus infections
WO2010109009A1 (en) 2009-03-27 2010-09-30 Protea Biopharma N.V. Methods for the detection and treatment of aberrant prion disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US4952394A (en) * 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
AU4402589A (en) * 1988-09-28 1990-04-18 Ideon Corporation Combination enzyme immunotherapeutics

Also Published As

Publication number Publication date
EP0752872A1 (de) 1997-01-15
JPH10503921A (ja) 1998-04-14
ATE412769T1 (de) 2008-11-15
AU701529B2 (en) 1999-01-28
EP0752872A4 (de) 2005-01-19
CA2187200A1 (en) 1995-10-12
AU2459995A (en) 1995-10-23
EP0752872B1 (de) 2008-10-29
WO1995026743A1 (en) 1995-10-12

Similar Documents

Publication Publication Date Title
ATE412769T1 (de) Nadh-oxidase als zielmolekül in diagnose und therapie
Smith et al. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure
JP4451930B2 (ja) 一酸化窒素の生成を阻害するテトラサイクリン化合物の使用方法
PT645142E (pt) Nova substancia fisiologicamente activa
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
ATE315789T1 (de) Elisa für vegf
Djeu et al. Selective growth of natural cytotoxic but not natural killer effector cells in interleukin-3
Catena et al. Necrotizing fasciitis: a dramatic surgical emergency
ES2138729T3 (es) Metodos de diagnostico de la preeclampsia.
US5605810A (en) NADH oxidase assay for neoplasia determination
Yan et al. Clinical implications of increased expression of CD40L in patients with acute coronary syndromes
Gau et al. Humic acid suppresses the LPS-induced expression of cell-surface adhesion proteins through the inhibition of NF-κB activation
Callen et al. Vesiculopustular eruption in a patient with ulcerative colitis
Mahon et al. Studies on the absorption and distribution of doxycycline in normal patients and in patients with severely impaired renal function
Boulton et al. Effect of L-Dopa therapy on urinary p-tyramine excretion and EEG changes in Parkinson's disease
EP2357223A3 (de) Humane Stammzellen und Verfahren zur Verwendung
HUT72700A (en) Method for in vitro quantitative assessment of protein activity related multidrug resistance of tumors in biological samples
FR2846426B1 (fr) Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
Sawada et al. Favorable response to lymphoblastoid interferon-alpha in children with chronic hepatitis C
Glackin et al. E. Cystic fibrosis
Finkel et al. Fluorometric and microbiological assays for rifampicin and the determination of serum levels in the dog
Agrup et al. 5-S-cysteinyldopa in the urine of melanoma patients
Isildar et al. DNA damage in intact cells induced by bacterial metabolites of chloramphenicol
BR9707776A (pt) Utilização da il-7 no tratamento das doenças autoimunes em especial o diabetes mellitus dependente de insulina
Marino et al. Bacteremic pneumococcal pneumonia and myoglobinuric renal failure

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee